<DOC>
	<DOCNO>NCT02871297</DOCNO>
	<brief_summary>Evaluation long-term safety tolerability vortioxetine child adolescent patient Diagnostic Statistical Manual Mental Disorders , 5th edition ( DSM-5™ ) diagnosis MDD</brief_summary>
	<brief_title>Long-term , Open-label , Flexible-dose , Extension Study Vortioxetine Child Adolescent Patients With Major Depressive Disorder ( MDD ) From 7 18 Years Age</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Vortioxetine</mesh_term>
	<criteria>The patient male female child age ≥7 &lt; 12 year adolescent age ≥12 ≤18 year leadin study ( 12709A 12710A ) . The patient must complete Study 12709A 12710A ( Visit 12 , Completion Visit ) immediately prior enrolment extension study . The patient primary diagnosis MDD entry study 12709A 12710A , diagnose accord DSM5™ . The patient indicate longterm treatment vortioxetine accord clinical opinion Investigator . For patient age ≥7 ≤17 year Baseline visit ; patient able understand Informed Assent Form , parent ( ) /legal representative ( ) able read understand Informed Consent Form . For patient turn 18 year leadin study 12710A ; patient sign Informed Consent Form . The patient diagnose another psychiatric disorder ( example mania , bipolar disorder , schizophrenia psychotic disorder ) study 12709A 12710A . The patient attentiondeficit/hyperactivity disorder ( ADHD ) require pharmacological treatment stimulant medication . Other protocoldefined inclusion exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>adolescent</keyword>
	<keyword>child</keyword>
</DOC>